Design, Synthesis, And Structure-Activity Relationship Of N-Aryl-N '-(Thiophen-2-Yl)Thiourea Derivatives As Novel And Specific Human Tlr1/2 Agonists For Potential Cancer Immunotherapy

JOURNAL OF MEDICINAL CHEMISTRY(2021)

引用 18|浏览9
暂无评分
摘要
The previous virtual screening of ten million compounds yielded two novel nonlipopeptide-like chemotypes as TLR2 agonists. Herein, we present the chemical optimization of our initial hit, 1-phenyl-3-(thiophen-2-yl)urea, which resulted in the identification of SMU-C80 (EC50 = 31.02 +/- 1.01 nM) as a TLR2-specific agonist with a 370-fold improvement in bioactivity. Mechanistic studies revealed that SMU-C80, through TLR1/2, recruits the adaptor protein MyD88 and triggers the NF-kappa B pathway to release cytokines such as TNF-alpha and IL-1 beta from human, but not murine, cells. To the best of our knowledge, it is the first species-specific TLR1/2 agonist reported until now. Moreover, SMU-C80 increased the percentage of T, B, and NK cells ex vivo and activated the immune cells, which suppressed cancer cell growth in vitro. In summary, we obtained a highly efficient and specific human TLR1/2 agonist that acts through the MyD88 and NF-kappa B pathway, facilitating cytokine release and the simultaneous activation of immune cells that in turn affects the apoptosis of cancer cells.
更多
查看译文
关键词
cancer immunotherapy,synthesis
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要